Platform combined with virotherapy targets cancerous cells while protecting healthy tissue of key organs

21-Oct-2020

Merck announced that Combined Therapeutics Inc., Cambridge, Massachusetts, USA, has been selected as the North American winner of its 2020 Advance Biotech Grant Program. The biotechnology company was selected for its innovative nucleic acid platform which, combined with virotherapy, has the ...

more

Investment of more than € 140 million creates approximately 55 new jobs

12-Oct-2020

Merck celebrated the topping-out ceremony for its new membrane production plant in Darmstadt, Germany. With the new facility, the company plans to expand manufacturing of Millipore Express® membranes, which are critical components in Millipore Express® filters and help ensure the sterility of ...

more

Two internationally experienced managers to join Executive Board

30-Sep-2020

Stefan Oschmann will hand over the Chair of the Executive Board of Merck to Belén Garijo in 2021. The Board of Partners of E.MerckKG has appointed Garijo as new Chair of the Executive Board and CEO of Merck effective May 1, 2021. She is currently Vice Chair of the Executive Board and Deputy CEO ...

more

From today’s perspective targeted smaller to medium-sized acquisitions after 2022 more likely than major transformative deals

17-Sep-2020

Merck expects to deliver continued profitable growth in the coming years despite a challenging market environment. Today at its virtual Capital Markets Day, the company presented to analysts and investors the progress made in realizing the growth and expansion phase of its strategy for the period ...

more

Creates one of the largest single-digit nanogram containment manufacturing facilities for high-potent active pharmaceutical ingredient (HPAPI) production

10-Sep-2020

Merck announced a € 59 million expansion of its HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin, USA. This investment will allow large-scale manufacturing of increasingly potent compounds for therapies that have the potential to treat cancer. ...

more

Healthcare and Performance Materials more strongly affected by the Covid-19 pandemic than Life Science

06-Aug-2020

Merck registered the effects of the Covid-19 pandemic in all business sectors in the second quarter. Healthcare and Performance Materials were affected most strongly. In comparison with the year-earlier quarter, Group sales increased by 3.7% to € 4.1 billion. EBITDA pre, the Group’s most ...

more

Supports growing reference materials business

16-Jul-2020

Merck has announced plans to build a new, € 18 million laboratory facility in Buchs, Switzerland to support the company’s rapidly growing reference materials business. The company anticipates that about two dozen jobs will be created. "Researchers in testing labs around the world use Merck’s ...

more

Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO

16-Jul-2020

The Board of Partners of E.MerckKG appointed Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO of Merck KGaA. She will maintain her current Executive Board responsibilities. “The appointment of Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO recognizes her ...

more

Prof. Sieber is developing approaches against multi-resistant pathogens

14-Jul-2020

Merck, a leading science and technology company, today announced the winner of the Future Insight Prize 2020, worth €1million. This year’s topic “Multi-Drug Resistance Breaker” relates to the health category. Prof.Stephan Sieber (44) is being awarded the Future Insight Prize 2020 for his ...

more

VAR2 Pharmaceuticals selected for its development of a drug-conjugated malaria protein

10-Jul-2020

Merck, a leading science and technology company, today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program. Copenhagen, Denmark-based biotechnology company VAR2 Pharmaceuticals was chosen for its development of a promising novel ...

more